MedTech Terms
    The authoritative reference
    All terms

    Data Safety Monitoring Board

    Independent committee that periodically reviews accumulating safety and (sometimes) efficacy data during a trial.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    DSMBs (also DMC) make recommendations to continue, modify, or stop a trial based on safety, futility, or overwhelming benefit. Their charter, membership, and stopping rules are pre-specified.
    What the regulation says
    The FDA guidance "Establishment and Operation of Clinical Trial Data Monitoring Committees" outlines expectations for DSMBs, particularly for trials with vulnerable populations, high-risk interventions, or those with early stopping points. Similarly, ICH E6(R2) Good Clinical Practice guidelines emphasize the importance of independent data monitoring for ensuring subject safety and data integrity during clinical trials.

    What this means in practice

    Required or strongly recommended for pivotal trials with mortality endpoints, vulnerable populations, or interim analyses.

    Examples

    • A Class III medical device clinical trial for a novel implantable cardiac device establishes a DSMB to monitor for adverse events, given the device's invasive nature and potential impact on patient mortality.
    • A pharmaceutical company conducting a Phase III trial for a new oncology drug forms a DSMB to evaluate interim efficacy and safety data, as the study involves a vulnerable patient population and has pre-specified interim analysis points.
    • A clinical investigator working on an NIH-funded study for a rare pediatric disease is required to convene a DSMB due to the involvement of a vulnerable population and the potential for serious outcomes.
    Common pitfalls
    • •Failing to clearly define the DSMB's charter, including its roles, responsibilities, and reporting structure, can lead to operational inefficiencies.
    • •Not ensuring the independence of DSMB members from the trial sponsor and investigators can compromise objectivity and regulatory acceptance.
    • •Inadequate definition of stopping rules or interim analysis plans can create ambiguity and delay critical decisions.
    • •Ignoring DSMB recommendations without proper justification can result in regulatory non-compliance and ethical concerns.
    • •Lack of documented communication channels and procedures between the DSMB, sponsor, and regulatory authorities can lead to misunderstandings and delays.

    Frequently asked questions

    A DSMB's primary role is to protect the safety of trial participants and to ensure the ethical conduct and scientific integrity of a clinical trial by periodically reviewing unblinded accumulating data.
    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    FDA·1NIH·1ICH·1
    1. 1
      FDA DMC Guidance
      Verified
      FDAfda.gov
    2. 2
      ClinicalTrials.gov
      Verified
      NIHclinicaltrials.gov
    3. 3
      ICH Guidelines
      Verified
      ICHich.org

    Inline markers like [1] jump to the matching reference above.